O
OpenEvidence
Health Tech & Medtech · Miami, United States · Founded 2021 Decacorn
AI-driven clinical decision support enhancing healthcare outcomes at the point of care
Global footprint
Where OpenEvidence has talent and traffic
(9 of 112 staff)
across markets
Patent intelligence
$210k patent portfolio · 1 active families
Where OpenEvidence concentrates vs peers
Each axis is a top-10 topic across OpenEvidence and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Capital deployed
OpenEvidence's 1 investments and acquisitions.
Every disclosed deal where OpenEvidence appeared as a backer or acquirer, 2025–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
1 deals across OpenEvidence's capital deployment.
Where the deals concentrate by sector, stage, and decade.
02 · Portfolio market map
OpenEvidence's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Sentiment on X
What X is saying about OpenEvidence
An AI-synthesized read of the highest-engagement posts about OpenEvidence on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OpenEvidence on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.